Global AMR R&D Hub

Global AMR R&D Hub
Name	Global AMR R&D Hub
Formation	2018
Type	International initiative
Headquarters	Berlin
Region served	Worldwide

Global AMR R&D Hub is an international initiative coordinating research and development responses to antimicrobial resistance. It links funding, policy and scientific actors to accelerate innovation in antimicrobial resistance countermeasures and aligns stakeholders across multilateral platforms. The Hub interfaces with major institutions to inform strategic investments and complements efforts by regulatory, funding and health organizations worldwide.

Overview

The Hub serves as a convening and data coordination platform connecting stakeholders such as the World Health Organization, European Commission, G20, United Nations, World Bank, and national agencies like the National Institutes of Health and National Institute for Health and Care Research. It aggregates data from funders including the Bill & Melinda Gates Foundation, Wellcome Trust, CARB-X, and the Coalition for Epidemic Preparedness Innovations while interfacing with regulatory bodies such as the European Medicines Agency and U.S. Food and Drug Administration. The Hub produces dashboards and priority-setting outputs that inform actors like the Global Fund, Gavi, Organisation for Economic Co-operation and Development, and academic institutions including Johns Hopkins University, Imperial College London, and the Karolinska Institutet.

History and Establishment

The Hub was launched following high-level advocacy at forums such as the 2016 United Nations General Assembly discussions on antimicrobial resistance and outcomes from the 2016 G20 health agenda. Its formation drew on recommendations from commissions including the Review on Antimicrobial Resistance chaired by Jim O'Neill and consultations involving agencies like the World Health Organization, Food and Agriculture Organization, and World Organisation for Animal Health. Founding partners included ministries from Germany, United Kingdom, Japan, and United States, with inaugural events held in coordination with institutions such as the Berlin Science Week and meetings at venues like the Charlemagne Building in Brussels.

Governance and Funding Mechanisms

Governance structures bring together public and private funders, represented by entities such as the Gavi, the Vaccine Alliance, European Investment Bank, Asian Development Bank, and national research councils like the German Research Foundation and Japan Agency for Medical Research and Development. Advisory bodies include scientific advisors from universities such as Harvard University and University of Oxford and expert groups drawn from the Wellcome Trust, Bill & Melinda Gates Foundation, and Centers for Disease Control and Prevention. Funding mechanisms tracked by the Hub encompass grants from bilateral agencies like United States Agency for International Development and pooled instruments resembling mechanisms used by the Global Fund and European Commission research programmes such as Horizon 2020 and Horizon Europe.

Key Activities and Initiatives

Key activities include the development of an R&D funding dashboard used by stakeholders including CARB-X, European Medicines Agency, U.S. Department of Health and Human Services, and academic consortia at LSHTM. The Hub supports priority-setting exercises aligned with reports from the Review on Antimicrobial Resistance, technical guidance from the World Health Organization, and policy platforms like the Global Health Security Agenda. Initiatives address discovery pipelines, clinical trials coordination with partners such as International Clinical Trials Registry Platform, and incentives models informed by economic analyses similar to outputs from the Organisation for Economic Co-operation and Development and research from Chatham House. The Hub also promotes stewardship and surveillance linkages with networks including European Centre for Disease Prevention and Control, Africa Centres for Disease Control and Prevention, and regional entities such as PAHO.

Partnerships and Global Collaboration

Partnerships span multilateral and bilateral organizations, philanthropic bodies, private sector firms, and academic networks. Collaborators include World Health Organization, Food and Agriculture Organization, World Organisation for Animal Health, Bill & Melinda Gates Foundation, Wellcome Trust, CARB-X, CEPI, and universities like University of Cape Town and University of São Paulo. The Hub coordinates with policy fora such as the United Nations General Assembly, G20 Health Working Group, and finance discussions at the IMF to link R&D priorities with fiscal instruments used by entities such as the European Investment Bank and national treasuries.

Impact and Criticism

The Hub has influenced transparency of global R&D funding flows, informing decisions by funders including Gavi, the Vaccine Alliance and national agencies such as National Institutes of Health. Its dashboards and reports have been cited in policy discussions at the United Nations and research planning at institutions like Johns Hopkins University and Imperial College London. Criticisms focus on scope and influence relative to entrenched incentives in pharmaceutical markets represented by multinational corporations such as Pfizer, Roche, and GlaxoSmithKline and the challenge of mobilizing sustainable pull incentives similar to proposals discussed in reports by Chatham House and the Review on Antimicrobial Resistance. Observers from advocacy groups and civil society networks, including MSF and academic critics at London School of Economics, have called for more binding financing commitments and clearer links to procurement mechanisms used by Gavi and the Global Fund.

Category:International medical organizations